U.S. Respiratory Syncytial Virus (RSV) Vaccine

In The News,

Sep 19 2022

U.S. Respiratory Syncytial Virus (RSV) Vaccine

Informed the client about clinical trial strategy to optimize a positive ACIP recommendation and prepare for key access risks and opportunities for an RSV vaccine, leveraging ADVI’s deep expertise in US pricing and market access trends and work experience with ACIP/CDC.